Clinical Evidence
Why Clinical Studies Matter Under MDR
- Clinical safety
- Clinical performance
- Clinical benefit
This is achieved through a Clinical Evaluation (Article 61, Annex XIV), often supported by clinical investigations (Annex XV). For many Class IIa, IIb, and III devices, clinical studies are no longer optional they are a regulatory and commercial necessity. Strong clinical evidence doesn’t just satisfy regulators, it builds trust with clinicians, payers, and patients.
Strong clinical evidence doesn’t just satisfy regulators—it builds trust with clinicians, payers, and patients.
Prospective Clinical Studies
A prospective clinical study is a planned investigation where patients are followed forward in time after receiving the device. Outcomes are predefined and collected according to a Clinical Investigation Plan (CIP). These studies may be:
- Single-arm (device only)
- Comparative (against standard of care or literature benchmarks)
When Prospective Studies Work Best
Prospective studies are widely accepted under MDR when:
- The device is Class IIa or IIb
- The technology is incremental or well-established
- Clinical benefit is already known
- Randomization is impractical or unethical
Key Benefits
- Faster study start-up
- Lower cost and complexity
- Strong real-world relevance
- Often sufficient for CE marking when well justified
Limitations
- Higher potential for bias
- Weaker evidence for novel or high-risk devices
- May not support superiority claims
Randomized Controlled Trials (RCTs)
When MDR Typically Expects an RCT
Notified Bodies often expect RCTs for:
- Class III devices
- Implantable devices
- Novel or breakthrough technologies
- Claims of superior clinical performance
Key Benefits
- Highest level of scientific credibility
- Minimizes bias
- Strong support for benefit–risk assessment
- Highly persuasive for regulators and investors
Limitations
- Higher cost and longer timelines
- Operational and ethical challenges
- Not always feasible for every device
Prospective Study vs RCT — At a Glance
| Feature | Prospective Study | Randomised Controlled Trial |
|---|---|---|
| Study design | Observational or comparative | Comparative |
| Randomisation | No | Yes |
| Evidence strength | Moderate | High |
| Typical MDR use | Class IIa / IIb | Class IIb / III |
| Cost & complexity | Lower | Higher |
| Suitable for novel devices | Sometimes | Preferred |
Choosing the Right Clinical Strategy
A Prospective Study May Be Sufficient If:
- Your device is an iteration of existing technology
- You can justify a state-of-the-art comparison
- The risk profile is moderate
- You aim for efficient market entry
An RCT Is Advisable If:
- Your device is innovative or implantable
- Clinical benefit is not yet established
- You claim superiority over existing solutions
- Long-term market acceptance is critical
Choosing the wrong study design is one of the most common causes of MDR delays.
Beyond CE Marking: The Market Value of Strong Clinical Evidence
Well-designed clinical studies can help you:
- Accelerate Notified Body approval
- Strengthen clinical adoption
- Support pricing and reimbursement
- Increase investor confidence
- Reduce post-market compliance risk
Clinical evidence is not just regulatory documentation—it is a commercial asset.
How We Help
We support medical device manufacturers with:
- Clinical strategy aligned to MDR expectations
- Study design (Prospective studies & RCTs)
- Clinical Investigation Plans (CIP)
- Clinical Evaluation Reports (CER)
- PMCF planning and execution
From clinical evidence to CE marking—and beyond.
Ready to Define Your Clinical Path?
The right clinical strategy can mean the difference between regulatory delay and market success. Let’s build evidence that regulators accept and markets trust.
Talk to us about your device class, novelty, and target claims to define a study approach that supports both CE marking and commercial adoption.
service related FAQ’s
A Biological Evaluation Report (BER) summarizes the device’s biological risk assessment, including device description, material characterization, exposure categorization, literature review, testing results (if applicable), and a toxicological risk assessment. It concludes whether the device is biologically safe and compliant with ISO 10993.
After Brexit, UKCA replaced CE marking in Great Britain. Manufacturers must comply with MHRA rules to legally place devices on the UK market.
As part of our commitment to regulatory compliance and risk management, we recommend that all non EU manufacturers have valid Product Liability Insurance when appointing us as their European Authorized Representative (EC REP). While it is not a legal requirement under MDR/IVDR for the EC REP to request proof of insurance, many Competent Authorities and Notified Bodies may inquire about the manufacturer’s liability coverage during inspections or audits. Having proper insurance also demonstrates due diligence and protects your business in the event of product-related claims in the European market. We do not provide insurance ourselves, but we can guide you on what to include based on your device risk class and market exposure.
Yes. If your company is based outside the EEA and wishes to market medical devices or IVDs in Europe, it is legally required to appoint an EC REP. This representative’s name and address must appear on the product labeling, outer packaging, or Instructions for Use (IFU).
Based on the number of models and varients the timeline may change. usually the timeline for class B is approx 8-10 montsh and Class D is 14 months.
